Dermatol. praxi. 2015;9(4):165-166

Shingles and the contemporary perspective on its treatment

MUDr. Hana Roháčová, Ph.D.
Klinika infekčních, parazitárních a tropických nemocí Nemocnice na Bulovce

Shingles is a relatively common illness which mainly effect persons with secondary immune deficiency. Most often the affected are elderly, but shingles can also be found among younger people including children. Shingles is the expression of the reactivation of the varicella -zoster virus, which, after primary infection, survive in sensitive ganglia of the human body. The cause of the reactivation is very often the weakening of the immune system. Discomfort arises with the appearance of the lesions, both in the location of the lesions as well as generalised symptoms. The greatest discomfort, however, comes with the elimination of the lesions. This is a result of post-herpetic neuralgia, which can affect a patient even a number of weeks or months after the initial infection. The intensity of this discomfort varies from mild to intense, and treatment is often difficult. The article discusses contemporary therapeutic treatments of the disease.

Keywords: shigles, clinical picture, treatment, prevention, post-herpetic neuralgia

Published: December 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Roháčová H. Shingles and the contemporary perspective on its treatment. Dermatol. praxi. 2015;9(4):165-166.
Download citation

References

  1. Murray RM, Rosenthal KS, Pfaller MA.Medical Mikrobiology, Elsevier Mosby, Fifth Edition, 2005.
  2. Epidat. Dostupné z: http://www.szu.cz/publikace/data/infekce-v-cr.
  3. Mandell GL, Bennett JE, Dolin R. Principles and Practise of Infectious Disease, 2005.
  4. Hope-Simpson RE. The nature of herpes zoster: a long term study and a new hypothesis. Proc R Soc Med. 1965; 58(1): 9-20 Go to original source... Go to PubMed...
  5. Ragozzino MW, Melton LJ 3rd, Kurland LT, et al. Population-based study of herpes zoster and its sequelae. Medicine. 1982; 61(5): 310-316. Go to original source... Go to PubMed...
  6. Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011; 305(2): 160-166. Go to original source... Go to PubMed...
  7. Černý R, Machala L. Neurologické komplikace HIV/AIDS, Nakladatelství Karolinum, Praha, 2007.
  8. Duniewicz M, Adam P. Neuroinfekce, Maxdorf, 1999.
  9. Roháčová H. Neuroinfekce, minimum pro praxi, Triton 2001.
  10. Gan EY, Tian EAL, Tey HL. Management of Herpes Zoster and Post-Herpetic Neuralgia. Am J.Clin. Dermatol 2013; 14: 77-85. Go to original source... Go to PubMed...
  11. Drolet M, Brisson M, Scgnader K, et al. Predictors of Postherpetic Neuralgia Among Patients With Herpes Zoster: A Prospective Study. The Journal of Pain, 2010; 11: pp.1211-1221. Go to original source... Go to PubMed...
  12. Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007; 44(Suppl 1): S1-26. Go to original source... Go to PubMed...
  13. Voros J, Koyfman A, Foran M. Do Corticosteroids Prevent Posherpetic neuralgia?. Annals of Emergency Medicine, 2014: 63. Go to original source... Go to PubMed...
  14. Sedláček D. Onemocnění vyvolaná virem varicella-zoster a možnosti jejich prevence, Vakcinologie 2014; 2: 83-88.
  15. Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010; 58(9): 1634-1641. Go to original source... Go to PubMed...
  16. Ultsch B, Weidemann F, Reinhold T, et al. Health economic evaluation of vaccinagtion strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany. BMC Health Serv Res. 2013; 13: 359. Go to original source... Go to PubMed...
  17. Voelker R. FDA expands age range for shinglkes vaccine. JAMA 2011; 305: 1526. Go to original source... Go to PubMed...




Dermatology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.